• Molecular Partners will present initial Phase 1/2a dose-escalation data for DLL3-targeting MP0712 at NACLC on Dec. 5, 2026.
• The study covers small cell lung cancer and other DLL3-expressing solid tumors; NACLC runs Dec. 4-6 in Scottsdale, Arizona.
• A separate MP0712 presentation on target expression is scheduled for Nov. 7 at the SNMMI Theranostics Conference, running Nov. 4-7 in Bethesda, Maryland.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Molecular Partners AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611050100OMX_____CNEWS_EN_GNW9870665_en) on November 05, 2026, and is solely responsible for the information contained therein.